In a 56-year-old man with foamy urine, mild hematuria (10 RBC/hpf), trace proteinuria, HbA1c 5.1%, two small renal calculi (4.3 mm in the right inner‑pole calyx and 3.5 mm in the left lower‑pole calyx) and well‑controlled hypertension on telmisartan 40 mg daily, what is the appropriate treatment and dosing?

Treatment Recommendation

Continue telmisartan 40 mg daily for hypertension, increase fluid intake to achieve at least 2 liters of urine output daily, and pursue conservative management with observation for the small kidney stones (4.3 mm and 3.5 mm), as they are likely to pass spontaneously and do not require immediate intervention.

Management Strategy

1. Kidney Stone Management

The small bilateral renal calculi (4.3 mm right, 3.5 mm left) located in calyces are asymptomatic and do not require active intervention at this time. Stones <5 mm have high spontaneous passage rates 1.

Primary stone prevention approach:

• Increase fluid intake to achieve ≥2 liters of urine output per day (not just fluid intake, but actual urine volume) 1
• This is the cornerstone of stone prevention and carries a weak recommendation with low-quality evidence, but represents the safest first-line approach
• Spread fluid intake throughout the day to maintain consistent dilution

Pharmacologic therapy is NOT indicated yet because:

• The patient has not demonstrated "active disease" (recurrent stone formation or symptomatic stones)
• Guidelines recommend pharmacologic therapy only when increased fluid intake fails to prevent recurrent stone formation 1, 2
• This is his first documented episode with incidentally discovered stones

If stones become symptomatic or recur despite adequate hydration:

• Consider thiazide diuretics (hydrochlorothiazide 25 mg twice daily OR 50 mg once daily, OR chlorthalidone 25 mg once daily) 2
• Potassium citrate therapy if 24-hour urine shows hypocitraturia
• Allopurinol if hyperuricosuria with normocalciuria is documented 2

2. Proteinuria and Hematuria Management

The trace albumin and 10 RBCs/hpf require evaluation but telmisartan is already providing renal protection.

Current telmisartan 40 mg is appropriate because:

• Telmisartan reduces proteinuria in hypertensive patients with kidney disease 3, 4
• The dose of 40 mg has demonstrated antiproteinuric effects 5
• Blood pressure is well-controlled, which is crucial for renal protection
• No dose adjustment needed for mild renal findings 6

Monitoring plan:

• Obtain 24-hour urine protein quantification (spot urine protein-to-creatinine ratio acceptable alternative)
• Check serum creatinine and estimated GFR
• Monitor serum potassium (telmisartan can cause hyperkalemia) 6
• If proteinuria is >1 g/24 hours or progressive, consider increasing telmisartan to 80 mg daily 3, 4

The foamy urine with trace albumin suggests:

• Mild glomerular leak, possibly related to hypertension
• Not yet at nephrotic range
• Telmisartan provides dual benefit: blood pressure control AND direct antiproteinuric effect through AT1 receptor blockade 7

3. Hypertension Management

Continue telmisartan 40 mg once daily 6

• Current regimen achieving good control
• No adjustment needed
• Provides renoprotection beyond blood pressure lowering

Important caveat: If adding thiazide for stone prevention in the future, the combination of telmisartan + hydrochlorothiazide has been studied and is safe, but requires closer monitoring of:

• Serum potassium (risk of hypokalemia from thiazide)
• Renal function
• Blood pressure (may drop further) 5

Key Monitoring Parameters

Short-term (1-3 months):

• Repeat urinalysis with microscopy
• 24-hour urine protein or spot protein-to-creatinine ratio
• Serum creatinine, eGFR, potassium
• Blood pressure monitoring

Long-term (6-12 months):

• Repeat renal ultrasound to assess stone position/size
• Annual metabolic stone evaluation if stones grow or new stones form
• Continue monitoring proteinuria and renal function

Critical Pitfalls to Avoid

1. Do not add thiazide diuretics prematurely - only indicated if stones recur despite adequate hydration 1, 2
2. Do not combine telmisartan with ACE inhibitors - combination therapy worsens renal outcomes despite reducing proteinuria more than monotherapy 8
3. Monitor potassium closely - telmisartan can cause hyperkalemia, especially with declining renal function 6
4. Do not ignore the proteinuria - even trace amounts warrant quantification and monitoring in a hypertensive patient

Summary of Specific Dosing

• Telmisartan: Continue 40 mg PO once daily
• Fluid intake: Target ≥2 L urine output daily (typically requires 2.5-3 L oral intake)
• No additional medications needed at this time